ClinicalTrials.gg
RecruitingNCT02057783RAPUpdated Feb 20, 2025

Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients with Resistant Hypertension

An interventional study of Physical activity in Hypertension, Resistant to Conventional Therapy and Sleep Apnea, sponsored by AGIR à Dom. Recruiting at 5 sites in 3 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by AGIR à Dom · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2015; still recruiting 11 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.

Read the detailed description
  1. Sleep apnea syndrome, resistant hypertension and cardio-vascular risk. There are many epidemiological and clinical cohort studies demonstrating an increasing cardiovascular risk associated with Obstructive Sleep Apnea Syndrome (OSAS). In epidemiological studies, OSA severity and incident hypertension are linked in a dose-response fashion. This is true even when taking into account usual confounding factors such as age, alcohol, tobacco consumption and body mass index. More specifically, OSAS is the leading cause of refractory hypertension and OSAS prevalence is up to 80% in patients with resistant hypertension.
  2. CPAP treatment impact for reducing blood pressure in OSAS patients with resistant hypertension A recent small sample size randomized trial (n=35) demonstrated the positive impact of CPAP in decreasing both clinical and 24-hour ambulatory blood pressure. Compared to the control group, awake systolic/diastolic ambulatory blood pressure monitoring decreased significantly in the continuous positive airway pressure group (Delta: +3.1±3.3 /+2.1±2.7 vs. -6.5±3.3/ 4.5±1.9mmHg in control and CPAP groups respectively, p\<0.05). Interestingly, the blood pressure changes were only observed while patients were awake, but not during nocturnal ambulatory blood pressure monitoring (Delta: +2.8±4.5/+1.8±3.5 vs. +1.6±3.5/+0.8±2.9mmHg, p=NS).

    HIPARCO Study, the largest Randomized Clinical Trial (RCT) in the field (n=194) recently published in JAMA (9 December 2013) also showed a significant but limited impact of CPAP on blood pressure. In an Intention To Treat analysis, CPAP significantly improved 24-h mean BP (3.0 mmHg; 95% CI 0.3 to 5.8; p=0.031) and DBP (3.2 mmHg; 95% CI 1.0 to 5.4; p=0.005) but not SBP (3.1; 95% CI -0.6 to 6.7; p=0.098). Moreover, patients in the CPAP group had 2.4 (1.2-5.1; p=0.019) times greater probability of recovering their dipper pattern. As CPAP alone is not enough in OSAS to sufficiently improve BP, further studies should address the efficacy of combined therapies in OSAS patients with resistant hypertension.

  3. Resistant hypertension and physical activity A study has recently explored the impact of a standardized exercise program in patients suffering from resistant hypertension7. In this RCT, the authors have demonstrated that the group of patients who have benefit from a physical activity program had their systolic and diastolic 24-hour ambulatory blood pressure monitoring decreasing by 6±12 and 3±7 mmHg respectively(p=0.03). Thus, the physical activity implemented in this population enabled a better control of blood pressure values. However the authors do not give any information about the presence of the absence of Sleep Apnea Syndrome (SAS) in this cohort.
  4. Study hypothesis:

Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.

Originality: Up to now no study has assessed the effects of combining physical activity with CPAP treatment in patients with sleep apnea and resistant hypertension. Our work is will be the first aiming at evaluating the benefit of this combination on the control of the systolic blood arterial pressure.

02

Conditions studied

  • Hypertension, Resistant to Conventional Therapy
  • Sleep Apnea
03

In context

Hypertension Resistant to Conventional Therapy

47 studies on the registry are indexed under Hypertension Resistant to Conventional Therapy; 3 are open to participants now.

This study's planned enrollment of 100 is above the median of 57 across 36 interventional studies indexed under Hypertension Resistant to Conventional Therapy.

Browse Hypertension Resistant to Conventional Therapy studies →

Lead sponsor

AGIR à Dom is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with an obstructive sleep apnea (apnea-hypopnea index > or equal to 15)
  • Patient with resistant hypertension uncontrolled by 3 or more antihypertensive agents
  • Ambulatory patient

Exclusion criteria

Exclusion Criteria:

  • Acute hepatic failure, biliary cirrhosis, cholestasis
  • Acute hypertension (SBP>= 180 mmHg and/or DBP >= 110 mmHg)
  • to CPAP treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Physical activity

    Obstructive sleep apnea and resistant hypertension controlled + physical activity

    Other: Physical activity

  • No intervention
    Control Group

    Obstructive sleep apnea and resistant hypertension controlled

Interventions

  • OtherPhysical activity

    Physical activity will carry out 3 times per week during 12 weeks for intervention arm

06

What researchers measure

Primary outcomes

  1. Systolic arterial blood pressure assessed by 24-hours home blood pressure monitoring

    Systolic arterial blood pressure assessed by 24-hours home blood pressure monitoring

    Time frame: To baseline at 12 weeks

Secondary outcomes

  1. diastolic arterial blood pressure assessed by 24-hours home blood pressure monitoring

    diastolic arterial blood pressure assessed by 24-hours home blood pressure monitoring

    Time frame: To baseline at 12 weeks

  2. Mean arterial blood pressure assessed by 24-hours home blood pressure monitoring

    Mean arterial blood pressure assessed by 24-hours home blood pressure monitoring

    Time frame: To baseline at 12 weeks

  3. Change in physical activity: number of hour per day of physical activity

    Change in physical activity: number of hour per day of physical activity

    Time frame: To baseline at 12 weeks

  4. pulse wave velocity

    pulse wave velocity

    Time frame: To baseline at 12 weeks

  5. Change in physical activity : Metabolic Equivalents (METS)

    Change in physical activity : Metabolic Equivalents (METS)

    Time frame: To baseline at 12 weeks

  6. Change in physical activity : Number of steps per day

    Change in physical activity : Number of steps per day

    Time frame: To baseline at 12 weeks

  7. Change in sleep duration: Sleep to lying position duration ratio

    Change in sleep duration: Sleep to lying position duration ratio

    Time frame: To baseline at 12 weeks

07

Study locations

3 of 5 sites recruiting
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
    Québec, Canada
    Recruiting
    • Simon Gakwaya · ContactSimon.Gakwaya@criucpq.ulaval.ca
    • Caroline Minville, MD · Contact
    • Frédéric Sériès, MD · Contact
    • Isabelle Boutin, MD · Contact
    • François Maltais, MD · Contact
  • Hopital Universitaire de Grenoble
    La Tronche, 38700, France
    Recruiting
    • Jean-Louis Pépin, MD PhD · ContactJPepin@chu-grenoble.fr
    • Sandrine Bouzon · Contactsbouzon@chu-grenoble.fr
    • Jean-Louis Pépin, Pr MD PhD · Contact
    • Renaud Tamisier, Pr MD PhD · Contact
    • Patrick Lévy, Pr MD PhD · Contact
    • Jean-Philippe Baguet, Pr MD PhD · Contact
    • Sandrine Launois, MD PhD · Contact
    • Olivier Ormezzano, MD PhD · Contact
  • Clinique Pasteur
    Toulouse, 31300, France
    Recruiting
    • Atul Pathak, MD PhD · Contactapathak@clinique-pasteur.com · +33 5 62 21 21 14
    • Atul Pathak, MD PhD · Contact
    • Laurence Adrover, MD PhD · Contact
    • Nicolas Combes, MD PhD · Contact
    • Isabelle Billiart, MD PhD · Contact
    • David Attias, MD PhD · Contact
    • Pierre Morinet, MD PhD · Contact
  • Hopitaux Universitaires de Genève
    Genève, Switzerland
    Withdrawn

    Not enrolling at this site.

  • Centre Hospitalier Universitaire Vaudois
    Lausanne, Switzerland
    Withdrawn

    Not enrolling at this site.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2015 (actual). Primary completion is estimated for Feb 2025, 118 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2014
First posted
Feb 7, 2014
StartActual
Mar 26, 2015
Primary completionEst.
Feb 18, 2025
CompletionEst.
Feb 18, 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02057783
Lead sponsor
AGIR à Dom
Responsible party
Sponsor
First posted
Feb 7, 2014
Start date
Mar 26, 2015
Primary completion
Feb 18, 2025 (estimated)
Completion
Feb 18, 2025 (estimated)
Last update
Feb 20, 2025

Study contacts

Jean-Louis Pépin, Pr MD PhD
Contact
JPepin@chu-grenoble.fr
Sandrine Bouzon
Contact
sbouzon@chu-grenoble.fr
Jean-Louis Pépin, Pr MD PhD
principal investigator · Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion